# A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection

> **NCT04544215** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Ruijin Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Drug-resistant

## Interventions

- **BIOLOGICAL:** Dosage 1 of MPCs-derived exosomes
- **BIOLOGICAL:** Dosage 2 of MPCs-derived exosomes
- **BIOLOGICAL:** No MPCs-derived exosomes

## Key facts

- **NCT ID:** NCT04544215
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-07-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Due to the COVID-19 pandemic, patient enrollment was slower than expected. After enrolling 26 patients, the trial was suspended as our partner company stopped producing haMPC-Exos.
- **Last updated:** 2024-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04544215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04544215, "A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04544215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*